Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis |
 |
 |
 |
|
Nanoparticles used to create topical Viagra rival By Nick Taylor, 29-Apr-2009 in-pharmacologist
Research presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA) suggests that topical application of a nanoparticle formulation could be effective and reduce side effects. The formulation consists of hydrogel and glass nanoparticle platform that is capable of sustained release of nitric oxide (NO), a compound that can aid ED by relaxing smooth muscle cells and expanding blood vessels so they fill with blood. Currently the treatment is in preclinical testing but has shown effectiveness in rats. The drug delivery formulation could also be applied to other ailments that would benefit from topical administration. Ira Sharlip, an AUA spokesman, said: "This is a very interesting concept which has potential to impact treatment of many conditions including erectile dysfunction if it can be translated from the animal lab to clinical practice. "It remains to be seen whether the effect of the nanoparticle technology is a local or a systemic effect." Details of the research The researchers investigated the effectiveness of the formulation by applying it the penis skin of seven rats and measuring the erectile response by intracorporal pressure/blood pressure (ICP/BP) ratio. Of the seven rats that had the formulation five experienced a positive change in the ICP/BP ratio and had visible erections. The average time for erectile response was 65 minutes. Sizeable market opportunities The 2005 market for ED drugs was valued at $1.95bn by Datamonitor and this is predicted to grow because of the ageing population, rising obesity and lessening of the social taboo. This represents a sizeable market for companies such as Pfizer and Eli Lilly and extending the life-cycle of their products will increasingly become a priority when generic competition approaches. Consequently alternative drug delivery technologies that can provide benefits such as lower doses and reduced side effects could become attractive in the coming years. |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis